EGFR-STAT3 signaling promotes formation of malignant peripheral nerve sheath tumors

Oncogene

Volumn 33, Issue 2, 2014, Pages 173-180

  Wu, J ^a   Patmore, D M ^a   Jousma, E ^a   Eaves, D W ^a   Breving, K ^a   Patel, A V ^a   Schwartz, E B ^b   Fuchs, J R ^b   Cripe, T P ^a   Stemmer Rachamimov, A O ^c   Ratner, N ^a  

^a CINCINNATI CHILDREN S HOSPITAL RESEARCH FOUNDATION   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

EGFR; MPNST; NF1; sarcoma; STAT3

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; JANUS KINASE 2; SHORT HAIRPIN RNA; STAT3 PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARCINOGENESIS; CONTROLLED STUDY; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; MALIGNANT NEOPLASTIC DISEASE; MOUSE; NERVE SHEATH TUMOR; NEUROFIBROMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; XENOGRAFT;

ANIMALS; CELLS, CULTURED; CURCUMIN; GENES, NEUROFIBROMATOSIS 1; HUMANS; JANUS KINASE 2; MICE; MICE, INBRED C57BL; NERVE SHEATH NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SARCOMA; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR;

EID: 84891940023     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2012.579     Document Type: Article

References (42)

1. Widemann BC. Current status of sporadic and neurofibromatosis type-Associated malignant peripheral nerve sheath tumors. Curr Oncol Rep 2009; 11: 322-328
2. Evans D, Baser M, McGaughran J, Sharif S, Howard E, Moran A. Malignant peripheral nerve sheath tumours in neurofibromatosis 1. J Med Genet 2002; 39: 311-314
3. Ferner RE, Gutmann DH. International consensus statement on malignant peripheral nerve sheath tumors in neurofibromatosis. Cancer Res 2002; 62: 1573-1577
4. Tucker T, Wolkenstein P, Revuz J, Zeller J, Friedman JM. Association between benign and malignant peripheral nerve sheath tumors in NF1. Neurology 2005; 65: 205-211
5. Ferner RE. Neurofibromatosis 1. Eur J Hum Genet 2007; 15: 131-138
6. Carroll SL, Ratner N. How does the Schwann cell lineage form tumors in NF1? Glia 2008; 56: 1590-1605
7. Katz D, Lazar A, Lev D. Malignant peripheral nerve sheath tumour (MPNST): The clinical implications of cellular signalling pathways. Expert Rev Mol Med 2009; 11: E30
8. Miller SJ, Jessen WJ, Mehta T, Hardiman A, Sites E, Kaiser S et al. Integrative genomic analyses of neurofibromatosis tumours identify SOX9 as a biomarker and survival gene. EMBO Mol Med 2009; 1: 236-248
9. Cichowski K, Shih TS, Schmitt E, Santiago S, Reilly K, McLaughlin ME et al. Mouse models of tumor development in neurofibromatosis type 1. Science 1999; 286: 2172-2176
10. Vogel KS, Klesse LJ, Velasco-Miguel S, Meyers K, Rushing EJ, Parada LF. Mouse tumor model for neurofibromatosis type 1. Science 1999; 286: 2176-2179
11. Joseph NM, Mosher JT, Buchstaller J, Snider P, McKeever PE, Lim M et al. The loss of Nf1 transiently promotes self-renewal but not tumorigenesis by neural crest stem cells. Cancer Cell 2008; 13: 129-140
12. Sun D, Tainsky MA, Haddad R. Oncogene mutation survey in MPNST cell lines enhances the dominant role of hyperactive Ras in NF1 associated pro-survival and malignancy. Transl Oncogenomics 2012; 5: 1-7
13. Yarden Y. The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities. Eur J Cancer 2001; 37(Suppl): S3-S8
14. DeClue JE, Heffelfinger S, Benvenuto G, Ling B, Li S, Rui W et al. Epidermal growth factor receptor expression in neurofibromatosis type-1 related tumors and NF1 animal models. J Clin Invest 2000; 105: 1-10
15. Li H, Velasco-Miguel S, Vass W, Parada L, DeClue J. Epidermal growth factor receptor signaling pathways are associated with tumorigenesis in the Nf1:p53 mouse tumor model. Cancer Res 2002; 62: 4507-4513
16. Perry A, Kunz S, Fuller C, Banerjee R, Marley E, Liapis H et al. Differential NF1, p16, and EGFR patterns by interphase cytogenetics (FISH) in malignant peripheral nerve sheath tumor (MPNST) and morphologically similar spindle cell neoplasms. J Neuropathol Exp Neurol 2002; 61: 702-709
17. Frohnert PW, Stonecypher MS, Carroll SL. Constitutive activation of the neuregulin-1/ErbB receptor signaling pathway is essential for the proliferation of a neoplastic Schwann cell line. Glia 2003; 43: 104-118
18. Keizman D, Issakov J, Meller I, Maimon N, Ish-Shalom M, Sher O et al. Expression and significance of EGFR in malignant peripheral nerve sheath tumor. J Neurooncol 2009; 94: 383-388
19. Luetteke N, Phillips H, Qiu T, Copeland N, Earp H, Jenkins N et al. The mouse waved-2 phenotype results from a point mutation in the EGF receptor tyrosine kinase. Genes Dev 1994; 8: 399-413
20. Ling B, Wu J, Miller S, Monk K, Shamekh R, Rizvi T et al. Role for the epidermal growth factor receptor in neurofibromatosis-related peripheral nerve tumorigenesis. Cancer Cell 2005; 7: 65-75
21. Yu H, Pardoll D, Jove R. STATs in cancer inflammation and immunity: A leading role for STAT3. Nat Rev Cancer 2009; 9: 798-809
22. Battle TE, Frank DA. The role of STAT3 in apoptosis. Curr Mol Med 2002; 2: 381-392
23. Vigneron A, Gamelin E, Coqueret O. The EGFR-STAT3 oncogenic pathway upregulates the Eme1 endonuclease to reduce DNA damage after topoisomerase I inhibition. Cancer Res 2008; 68: 815-825
24. Sherry MM, Reeves A, Wu JK, Cochran BH. STAT3 is required for proliferation and maintenance of multipotency in glioblastoma stem cells. Stem Cells 2009; 27: 2383-2392
25. Banerjee S, Byrd JN, Gianino SM, Harpstrite SE, Rodriguez FJ, Tuskan RG et al. The neurofibromatosis type 1 tumor suppressor controls cell growth by regulating signal transducer and activator of transcription-3 activity in vitro and in vivo. Cancer Res 2010; 70: 1356-1366
26. Lin L, Hutzen B, Zuo M, Ball S, Deangelis S, Foust E et al. Novel STAT3 phosphorylation inhibitors exhibit potent growth-suppressive activity in pancreatic and breast cancer cells. Cancer Res 2010; 70: 2445-2454
27. Wu J, Williams JP, Rizvi TA, Kordich JJ, Witte D, Meijer D et al. Plexiform and dermal neurofibromas and pigmentation are caused by Nf1 loss in desert hedgehog-expressing cells. Cancer Cell 2008; 13: 105-116
28. Stemmer-Rachamimov A, Louis D, Nielsen G, Antonescu C, Borowsky A, Bronson R et al. Comparative pathology of nerve sheath tumors in mouse models and humans. Cancer Res 2004; 64: 3718-3724
29. Beert E, Brems H, Daniels B, De Wever I, Van Calenbergh F, Schoenaers J et al. Atypical neurofibromas in neurofibromatosis type 1 are premalignant tumors. Genes Chromosomes Cancer 2011; 50: 1021-1032
30. Reilly KM, Broman KW, Bronson RT, Tsang S, Loisel DA, Christy ES et al. An imprinted locus epistatically influences Nstr1 and Nstr2 to control resistance to nerve sheath tumors in a neurofibromatosis type 1 mouse model. Cancer Res 2006; 66: 62-68
31. Reilly KM, Tuskan RG, Christy E, Loisel DA, Ledger J, Bronson RT et al. Susceptibility to astrocytoma in mice mutant for Nf1 and Trp53 is linked to chromosome 11 and subject to epigenetic effects. Proc Natl Acad Sci USA 2004; 101: 13008-13013
32. Walrath JC, Fox K, Truffer E, Gregory Alvord W, Quinones OA, Reilly KM. Chr 19(A/J) modifies tumor resistance in a sex-And parent-of-origin-specific manner. Mamm Genome 2009; 20: 214-223
33. Torres KE, Zhu QS, Bill K, Lopez G, Ghadimi MP, Xie X et al. Activated MET is a molecular prognosticator and potential therapeutic target for malignant peripheral nerve sheath tumors. Clin Cancer Res 2011; 17: 3943-3955
34. Shao H, Cheng HY, Cook RG, Tweardy DJ. Identification and characterization of signal transducer and activator of transcription 3 recruitment sites within the epidermal growth factor receptor. Cancer Res 2003; 63: 3923-3930
35. Fukuda A, Wang S, Morris 4th JP, Folias A, Liou A, Kim G et al. Stat3 and MMP7 contribute to pancreatic ductal adenocarcinoma initiation and progression. Cancer Cell 2011; 19: 441-455
36. Lesina M, Kurkowski M, Ludes K, Rose-John S, Treiber M, KlÖ ppel G et al. Stat3/ Socs3 activation by IL-6 transsignaling promotes progression of pancreatic intraepithelial neoplasia and development of pancreatic cancer. Cancer Cell 2011; 19: 456-469
37. Guryanova O, Wu Q, Cheng L, Lathia J, Huang Z, Yang J et al. Nonreceptor tyrosine kinase BMX maintains self-renewal and tumorigenic potential of glioblastoma stem cells by activating STAT3. Cancer Cell 2011; 19: 498-511
38. Marotta L, Almendro V, Marusyk A, Shipitsin M, Schemme J, Walker S et al. The JAK2/STAT3 signaling pathway is required for growth of CD44 CD24- stem cell-like breast cancer cells in human tumors. J Clin Invest 2011; 121: 2723-2735
39. Lo HW, Hsu SC, Xia W, Cao X, Shih JY, Wei Y et al. Epidermal growth factor receptor cooperates with signal transducer and activator of transcription 3 to induce epithelial-mesenchymal transition in cancer cells via up-regulation of TWIST gene expression. Cancer Res 2007; 67: 9066-9076
40. Miller SJ, Rangwala F, Williams J, Ackerman P, Kong S, Jegga AG et al. Large-scale molecular comparison of human schwann cells to malignant peripheral nerve sheath tumor cell lines and tissues. Cancer Res 2006; 66: 2584-2591
41. Frahm S, Mautner VF, Brems H, Legius E, Debiec-Rychter M, Friedrich RE et al. Genetic and phenotypic characterization of tumor cells derived from malignant peripheral nerve sheath tumors of neurofibromatosis type 1 patients. Neurobiol Dis 2004; 16: 85-91
42. Rosenbaum T, Rosenbaum C, Winner U, Muller HW, Lenard HG, Hanemann CO. Long-Term culture and characterization of human neurofibroma-derived Schwann cells. J Neurosci Res 2000; 61: 524-532